- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Roy S. Herbst, MD, PhD | Authors
Articles
Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010
February 26, 2021
The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.
Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer Care
June 15, 2020
Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with non-small cell lung cancer.
Roy S. Herbst, MD, PhD, Discusses ADAURA Trial and Future of Lung Cancer Treatment
June 12, 2020
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial
June 03, 2020
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
Immunotherapy in Lung Cancer
August 26, 2015
In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.
Future Directions of Monoclonal Antibody Use in Personalized Lung Cancer Therapy
November 30, 2010
With the new direction in research and clinical trials, treating patients who most benefit from treatment with minimal toxicity will continue to be the mainstay of personalized cancer therapy.
Inhalation Therapy for Lung Cancer ‘Primed for Growth,’ Investigator Says
March 01, 2005
This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.
Erlotinib Prolongs Survival in Never Smokers, Subgroup Analysis Shows
March 01, 2005
This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.
Congress Denies FDA Power to Regulate Tobacco Products
March 01, 2005
This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.
Investigators Seek Markers for Sensitivity to EGFR Inhibitors
March 01, 2005
This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.